IEA says it stands ready to tap emergency oil stocks, OPEC sees no need

The oil drilling rig Polar Pioneer is towed toward a dock in Elliott Bay in Seattle. The rig is the first of two drilling rigs Royal Dutch Shell is outfitting for Arctic oil exploration on May 14, 2015. (AP / Elaine Thompson)
The west's energy watchdog said on Friday it was ready to release oil stocks should the market experience shortages following Israel's attack on Iran, drawing criticism from rival OPEC which said the statement would only create fear in the market.
The International Energy Agency, representing oil consumers, and the Organization of the Petroleum Exporting Countries, representing some of the world's top oil producers, have in recent years clashed on global oil demand trajectories and the pace of the energy transition.
The IEA's head Fatih Birol said that while the oil market was well supplied, the agency would be ready to act if needed, adding that the agency's oil security system held US1.2 billion barrels of oil in strategic and emergency reserves.
OPEC Secretary General Haitham Al Ghais criticized Birol's statement, saying it 'raises false alarms and projects a sense of market fear through repeating the unnecessary need to potentially use oil emergency stocks.'
He said there were no developments in supply or market dynamics that 'warrant unnecessary measures.'
Oil prices jumped sharply after Israel launched a barrage of strikes across Iran on Friday, saying it had attacked nuclear facilities and missile factories and killed a swathe of military commanders in what could be a prolonged operation to prevent Tehran building an atomic weapon.
Oil prices were trading seven per cent higher, their biggest daily spike since 2022 when Russia invaded Ukraine.
The United States and its allies, in coordination with the IEA, last tapped emergency oil stocks in early 2022 after the Russian invasion of Ukraine, a decision that OPEC heavily criticized at the time.
While Israel has stopped short of targeting Iran's energy facilities, market participants are wary the situation may escalate further leading to damage to energy infrastructure in Iran or its neighbors, as well as a blockade of the Strait of Hormuz.
In September 2019, Iran-backed Houthi militias in Yemen launched a drone attack on Saudi Aramco's 2222.SE Abqaiq oil processing plant, knocking 5.7 million bpd of Saudi oil production offline and sending the oil market into a frenzy.
Iran's diplomatic relations with its Gulf neighbors Saudi Arabia and the United Arab Emirates have improved significantly since that attack, though there are still some concerns in the region of a repeat of the Abqaiq scenario.
'Oil has already spiked ... and its ultimate landing point will likely hinge on whether Iran revives the 2019 playbook and targets tankers, pipelines, and key energy facilities across the region,' RBC Capital Markets analyst Helima Croft said in a note following the Israeli attack.
(Reporting by Ashitha Shivaprasad in Bengaluru and Ahmad Ghaddar in London, Editing by Louise Heavens and Susan Fenton)

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

National Post

20 minutes ago

• National Post

Samsara Announces 2025 North America Customer Advisory Board to Accelerate AI-Powered Safety and Efficiency Breakthroughs

Article content Members play a pivotal role in shaping Samsara solutions; meeting to be held today at the premier event for physical operations, Samsara Beyond Article content SAN DIEGO — Samsara Inc. ('Samsara') (NYSE: IOT), the pioneer of the Connected Operations ® Platform, today announced its 2025 North America Customer Advisory Board. Its members are at the forefront of the world's most complex operations, managing vast frontline workforces and asset portfolios, and are responsible for significant economic value. Recognizing the transformative impact of Samsara's AI-powered platform, these leaders have joined forces to help shape Samsara's product roadmap and to exchange insights for safer, more efficient, and sustainable operations for all. Article content 'I've seen firsthand the impact Samsara's platform has made on the industry, and I'm excited to play a role in what's to come,' said Jeff Wright, Vice President of Transportation at Quikrete. 'At Quikrete, we manage complex operations that greatly benefit from Samsara's real-time data. With AI's potential only growing in operations, this is an important moment to partner and drive innovation.' Article content The distinguished members of Samsara's 2025 North America Customer Advisory Board include leaders from organizations such as: Article content ArcBest, Don Davis, Vice President, Fleet Services Artera, Adam Lanier, Chief Safety Officer AWP Safety, Jarrod Wachter, Chief Operating Officer BNSF Railway, Matthew Igoe, Executive Vice President, Operations DHL Express, Fred Matthews, Senior Project Manager, Safety Programs DHL Supply Chain, Jennifer Miller, Vice President, Integrated Transportation Estes, Todd Florence, Chief Information Officer Ferrellgas, Tamria Zertuche, President and Chief Executive Officer First Student, Sean McCormack, Chief Information Officer Frontier Communications, Doug Spurlin, Senior Director, Operations Liberty Energy, Michael Tuomi, Director, HSE and Training MacAllister, Bill Dollard, Director, Corporate Fleet Martin Marietta, Greg Lahrman, Vice President, Enterprise Excellence Maxim Crane Works, Dennis Collins, Vice President, Operations Mohawk Industries, Andy Yearout, Senior Vice President, Supply Chain NiSource, Bill Jefferson, Chief Operations Officer Nutrien Ag Solutions, Adam Lorenz, Senior Director, Fleet and Procurement Operations Performance Food Group, Thomas Olitsky, Vice President, Safety Pike, James Banner, Senior Vice President, Administration and Safety Primoris, Eric Amlee, Vice President, Fleet Operations PS Logistics, Mauricio Paredes, Vice President, Technology Quikrete, Jeff Wright, Vice President, Transportation Republic Services, Brett Rogers, Vice President, Operations Technology Saia, Rohit Lal, Executive Vice President and Chief Information Officer Southeastern Freight Lines, Kerry Stritt, Vice President, Fleet Services Southern California Edison, Karan Kumar, Director, Transportation Services Sysco, Kevin Thomas, Vice President, Global EHSS and Asset Protection Tyson Foods, Phil Vanhook, Managing Director, Transportation Operations UNFI, Tehzin Chadwick, Senior Vice President, Safety UniFirst, Matt Croatti, Senior Vice President, Operations Univar Solutions, Rob McRae, Vice President, Transportation USIC, Tom Karnowski, Vice President, EHS XPO, Greg Pawelski, Vice President, Health and Safety Article content Samsara's platform is advanced by the direct input of its Customer Advisory Board, ensuring its products meet the evolving needs of physical operations. Leaders' insights have shaped innovations like Recognition, a feature that uses AI insights and real-time driver data to identify and celebrate outcomes like safe driving streaks and consistent compliance with regulations. In addition, they've influenced the Asset Tag, a small ruggedized tracker that helps customers find lost or stolen assets, reduce downtime, and streamline inventory management. Article content 'Being on Samsara's Customer Advisory Board has been incredibly valuable because we get to collaborate with other industry leaders and quickly see the results of our product feedback,' said James Banner, Senior Vice President of Administration and Safety at Pike. 'It's a unique opportunity to shape products that transform the way we operate. The Asset Tag is a prime example: we advised on use cases and the product has now reduced theft and improved efficiency for Pike and many others.' Article content Samsara's commitment to building market-leading technology and fostering a collaborative community is foundational to its mission. Its Customer Advisory Board is just one example that demonstrates this, others include Samsara User Groups, Samsara Spark, and Samsara Beyond. Samsara's forums create a space where the industry can connect, share their most pressing challenges, exchange ideas, and spark innovation. These moments drive real-world outcomes and operational excellence. Another popular program, Samsara Professional Credentials, celebrates the expertise of individuals who complete tailored learning experiences through the Samsara Academy. Samsara is proud to help the industry solve complex challenges with technology and community. Article content 'With all the changes AI is bringing to physical operations, the partnership between industry leaders and technology innovators has never been more important,' said Kiren Sekar, Chief Product Officer at Samsara. 'Our advisory board isn't just about adapting to change, but actively shaping the future of this industry and making a lasting impact, together.' Article content Samsara (NYSE: IOT) is the pioneer of the Connected Operations ® Platform, which enables organizations that depend on physical operations to harness Internet of Things (IoT) data to develop actionable insights and improve their operations. With tens of thousands of customers across North America and Europe, Samsara is a proud technology partner to the people who keep our global economy running, including the world's leading organizations across construction, transportation and warehousing, field services, manufacturing, retail, logistics, and the public sector. The company's mission is to increase the safety, efficiency, and sustainability of the operations that power the global economy. Article content Article content Article content

Globe and Mail

20 minutes ago

• Globe and Mail

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

NEEDHAM, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Charles Schoch as Chief Financial Officer (CFO). Mr. Schoch, who has served as interim CFO of Candel since January 2024, will transition to the CFO role permanently, effective immediately. 'Charles has demonstrated exceptional financial and organizational leadership during his tenure as interim CFO,' said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. 'He has effectively supported our strategic priorities in a complex market environment while maintaining disciplined capital management. His deep understanding of our business will continue to be instrumental as we advance our clinical pipeline, prepare for our Biologics License Application submission for CAN-2409 in localized prostate cancer, and execute on our near- and long-term corporate goals.' Since joining Candel in November 2021, Mr. Schoch has served in various financial reporting and accounting positions of increasing responsibility, most recently as VP of Finance and Corporate Controller, before being named interim CFO in January 2024. In his interim CFO role, Mr. Schoch developed significant investment banking relationships and has led the company through engagements with top-tier institutional investors, culminating in a previously-announced capital raise with net proceeds of approximately $86 million following the disclosure of positive results in the phase 3 clinical trial of CAN-2409 in localized prostate cancer in December 2024. In January 2025, he was promoted to Senior VP. During his time at Candel, Mr. Schoch has built a high-performing finance function that oversees Candel's financial close process, internal controls, SEC reporting, financial planning, procurement, payroll, and treasury operations. Mr. Schoch has also worked closely with Candel's executive leadership team on investor relations, business development, and financing initiatives. Prior to joining Candel, Mr. Schoch served as Corporate Controller at Corbus Pharmaceuticals from 2019 to 2021. Before Corbus, he spent seven years in PwC's Health Industry assurance practice where he served a diverse group of audit clients, ranging from pre-IPO to multinational public companies within the life sciences sector. Earlier in his career, Mr. Schoch worked for several Third Rock Venture portfolio companies as a financial and operational consultant. Mr. Schoch holds an M.B.A. and M.S.A. from Northeastern University and a B.S. in business administration with a concentration in finance from Elon University. 'I am honored to continue serving in this role and excited about the opportunities that lie ahead for Candel,' commented Mr. Schoch. 'Our strong financial foundation and disciplined approach to capital allocation and value creation position us well for sustainable growth. As we advance our promising clinical pipeline and prepare for key milestones, my focus remains on maintaining financial stability while strategically investing in our future. I look forward to working with our talented team on our goals of driving value for our stakeholders and ultimately helping to deliver clinically meaningful solutions to cancer patients in need.' About Candel Therapeutics Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). CAN-2409 plus prodrug (valacyclovir) has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy and localized primary prostate cancer. The FDA most recently also granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and Orphan Drug Designation to CAN-2409 for the treatment of PDAC. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, expectations regarding the submission of the BLA for CAN-2409 in intermediate-to-high-risk localized prostate cancer; and expectations regarding the therapeutic benefit of the Company's platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult to treat, solid tumors. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor Contact: Theodore Jenkins VP, Investor Relations and Business Development Candel Therapeutics, Inc. tjenkins@

CTV News

26 minutes ago

• CTV News

Clerk who denied same-sex marriage licences in 2015 is still fighting Supreme Court's ruling

Rowan County Clerk Kim Davis, right, talks with David Moore following her office's refusal to issue marriage licenses at the Rowan County Courthouse in Morehead, Ky., on Sept. 1 2015. (AP Photo/Timothy D. Easley, File) The Kentucky county clerk who became known around the world for her opposition to the U.S. Supreme Court's 2015 ruling that legalized same-sex marriage is still arguing in court that it should be overturned. Kim Davis became a cultural lightning rod 10 years ago, bringing national media and conservative religious leaders to eastern Kentucky as she continued for weeks to deny the licenses. She later met Pope Francis in Rome and was parodied on 'Saturday Night Live.' Kim Davis denied marriage licenses to same-sex couples Davis began denying marriage licenses to same-sex couples after the Supreme Court's landmark ruling in Obergefell v. Hodges on June 26, 2015. Videos of a same-sex couple arguing with Davis in the clerk's office over their denial of a license drew national attention to her office. She defied court orders to issue the licenses until a federal judge jailed her for contempt of court in September 2015. Davis was released after her staff issued the licenses on her behalf but removed her name from the form. The Kentucky Legislature later enacted a law removing the names of all county clerks from state marriage licenses. Davis cited her Christian faith Davis said her faith forbade her from what she saw as an endorsement of same-sex marriage. Faith leaders and conservative political leaders including former Arkansas Gov. Mike Huckabee and then-Kentucky Gov. Matt Bevin rallied to her cause. After her release from jail, Davis addressed the media, saying that issuing same-sex marriage licenses 'would be conflicting with God's definition of marriage as a union between one man and one woman. This would be an act of disobedience to my God.' Davis declined a request for an interview from The Associated Press for this story. A man who was denied a license ran for her office In 2018, one of the men who had confronted Davis over her defiance ran for her office. David Ermold said he believed people in Rowan County were sick of Davis and wanted to move on. When he went to file his papers for the Democratic primary, Davis, a Republican, was there in her capacity as clerk to sign him up. Sitting across a desk from each other, the cordial meeting contrasted the first time they met three years earlier. Both candidates lost; Ermold in the primary and Davis in the general election. She has not returned to politics. 10 years later, Davis wants the Supreme Court to reconsider same-sex marriage Davis' lawyers are attempting again to get her case before the Supreme Court, after the high court declined to hear an appeal from her in 2020. A federal judge has ordered Davis to pay a total of US$360,000 in damages and attorney fees to Ermold and his partner. Davis lost a bid in March to have her appeal of that ruling heard by a federal appeals court, but she will appeal again to the Supreme Court. Her attorney, Mat Staver of the Liberty Counsel, said the goal is affirm Davis' constitutional rights and 'overturn Obergefell.' Dylan Lovan, The Associated Press